FI3565844T3 - Menetelmiä syövän hoitamiseksi anti-pd-1 -vasta-aineilla - Google Patents
Menetelmiä syövän hoitamiseksi anti-pd-1 -vasta-aineilla Download PDFInfo
- Publication number
- FI3565844T3 FI3565844T3 FIEP18704101.7T FI18704101T FI3565844T3 FI 3565844 T3 FI3565844 T3 FI 3565844T3 FI 18704101 T FI18704101 T FI 18704101T FI 3565844 T3 FI3565844 T3 FI 3565844T3
- Authority
- FI
- Finland
- Prior art keywords
- antibody
- cancer
- use according
- chemotherapy
- intended
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims 11
- 201000011510 cancer Diseases 0.000 title claims 10
- 238000002512 chemotherapy Methods 0.000 claims 3
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 238000011277 treatment modality Methods 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 1
- 208000032818 Microsatellite Instability Diseases 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 238000011518 platinum-based chemotherapy Methods 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762444336P | 2017-01-09 | 2017-01-09 | |
| US201762477423P | 2017-03-27 | 2017-03-27 | |
| US201762491220P | 2017-04-27 | 2017-04-27 | |
| US201762556386P | 2017-09-09 | 2017-09-09 | |
| PCT/US2018/013029 WO2018129559A1 (en) | 2017-01-09 | 2018-01-09 | Methods of treating cancer with anti-pd-1 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3565844T3 true FI3565844T3 (fi) | 2023-05-09 |
Family
ID=61188903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP18704101.7T FI3565844T3 (fi) | 2017-01-09 | 2018-01-09 | Menetelmiä syövän hoitamiseksi anti-pd-1 -vasta-aineilla |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11407830B2 (enExample) |
| EP (2) | EP3565844B8 (enExample) |
| JP (2) | JP7110206B6 (enExample) |
| KR (1) | KR102606252B1 (enExample) |
| CN (1) | CN110382545A (enExample) |
| AU (2) | AU2018206481B2 (enExample) |
| BR (1) | BR112019014187A2 (enExample) |
| CA (1) | CA3049440A1 (enExample) |
| DK (1) | DK3565844T5 (enExample) |
| ES (1) | ES2945745T3 (enExample) |
| FI (1) | FI3565844T3 (enExample) |
| HU (1) | HUE061842T2 (enExample) |
| IL (1) | IL267804B2 (enExample) |
| MA (1) | MA47208A (enExample) |
| MX (1) | MX2019008207A (enExample) |
| PL (1) | PL3565844T3 (enExample) |
| PT (1) | PT3565844T (enExample) |
| SG (2) | SG10201913075RA (enExample) |
| TW (1) | TWI767976B (enExample) |
| WO (1) | WO2018129559A1 (enExample) |
| ZA (1) | ZA201904316B (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2010011088A (es) | 2008-04-09 | 2010-11-05 | Genentech Inc | Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad. |
| CA3037380A1 (en) | 2016-10-11 | 2018-04-19 | Agenus Inc. | Anti-lag-3 antibodies and methods of use thereof |
| EP3666794A1 (en) * | 2016-11-01 | 2020-06-17 | AnaptysBio, Inc. | Antibodies directed against programmed death- 1 (pd-1) |
| CN110382545A (zh) | 2017-01-09 | 2019-10-25 | 泰萨罗公司 | 用抗pd-1抗体治疗癌症的方法 |
| TWI879716B (zh) | 2017-05-09 | 2025-04-11 | 美商提薩羅有限公司 | 治療癌症的組合療法 |
| MA49144A (fr) | 2017-05-18 | 2020-03-25 | Tesaro Inc | Polythérapies pour le traitement du cancer |
| BR112020006039A2 (pt) | 2017-09-26 | 2020-10-06 | Tesaro, Inc. | formulações de niraparibe |
| CA3076515A1 (en) | 2017-09-30 | 2019-04-04 | Tesaro, Inc. | Combination therapies for treating cancer |
| MA50618A (fr) | 2017-10-06 | 2020-08-12 | Tesaro Inc | Polyrhérapies et leurs utilisations |
| KR20200119844A (ko) | 2018-02-13 | 2020-10-20 | 머크 샤프 앤드 돔 코포레이션 | 항-pd-1 항체를 사용한 암의 치료 방법 |
| TWI852940B (zh) * | 2018-09-04 | 2024-08-21 | 美商泰沙羅公司 | 治療癌症之方法 |
| EP3860988A1 (en) | 2018-10-03 | 2021-08-11 | Tesaro, Inc. | Crystalline forms of niraparib freebase |
| ES2967517T3 (es) | 2018-10-03 | 2024-04-30 | Tesaro Inc | Sales de niraparib |
| WO2020128908A2 (en) * | 2018-12-20 | 2020-06-25 | Medimmune, Llc | Methods for selection and expansion of t cells expressing pd-1 |
| US11613564B2 (en) * | 2019-05-31 | 2023-03-28 | ALX Oncology Inc. | Methods of treating cancer |
| AU2020407007A1 (en) * | 2019-12-18 | 2022-06-23 | Tesaro, Inc. | Biopharmaceutical compositions and related methods |
| CA3163564A1 (en) * | 2019-12-31 | 2021-07-08 | Xiaokun SHEN | A drug combination for treating tumors and its application |
| EP4096718A1 (en) | 2020-01-28 | 2022-12-07 | GlaxoSmithKline Intellectual Property Development Limited | Combination treatments and uses and methods thereof |
| JP7593669B2 (ja) * | 2020-02-18 | 2024-12-03 | イノベイション バイオ カンパニー リミテッド | コンパニオン診断用バイオマーカー組成物およびこれを含むコンパニオン診断用キット |
| EP4132490A4 (en) * | 2020-04-07 | 2024-04-24 | Metanoi Therapeutics, Inc. | ETHANOLAMINE FORMULATION FOR THE TREATMENT OF EPITHELIAL OVARIAN CARCINOMA |
| LT4157876T (lt) | 2020-05-26 | 2024-10-25 | Boehringer Ingelheim International Gmbh | Anti-pd-1 antikūnai |
| US20210395366A1 (en) * | 2020-06-18 | 2021-12-23 | Genentech, Inc. | Treatment with anti-tigit antibodies and pd-1 axis binding antagonists |
| WO2022025482A1 (ko) * | 2020-07-29 | 2022-02-03 | 재단법인 아산사회복지재단 | 스트렙토니그린 및 면역관문 억제제를 유효성분으로 포함하는 대장암 예방 및 치료용 조성물 |
| WO2022090529A1 (en) * | 2020-11-02 | 2022-05-05 | Ares Trading S.A. | Combination treatment of cancer |
| CN115607664A (zh) * | 2021-07-15 | 2023-01-17 | 嘉和生物药业有限公司 | 抗pd-1抗体在治疗宫颈癌中的应用 |
| WO2023076668A1 (en) * | 2021-10-29 | 2023-05-04 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Compositions and methods for treatment of cancer |
| WO2023153763A1 (ko) * | 2022-02-08 | 2023-08-17 | 고려대학교 산학협력단 | C-met의 에피토프 및 hif1alpha의 에피토프를 포함하는 암 백신 및 이의 용도 |
| AU2024252845A1 (en) | 2023-04-06 | 2025-10-16 | Glaxosmithkline Intellectual Property (No.4) Limited | Methods for treating and monitoring cancer |
| GB202308807D0 (en) | 2023-06-13 | 2023-07-26 | Ionctura Sa | Combinations |
| TW202509063A (zh) * | 2023-08-21 | 2025-03-01 | 瑞士商百濟神州瑞士有限責任公司 | 用抗lag3、抗pd-1和化學療法治療食管癌 |
Family Cites Families (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| EP0557459B1 (en) | 1990-11-13 | 1997-10-22 | Immunex Corporation | Bifunctional selectable fusion genes |
| WO1994028143A1 (en) | 1993-05-21 | 1994-12-08 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
| US5814618A (en) | 1993-06-14 | 1998-09-29 | Basf Aktiengesellschaft | Methods for regulating gene expression |
| US5464758A (en) | 1993-06-14 | 1995-11-07 | Gossen; Manfred | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
| EP1210428B1 (en) | 1999-08-23 | 2015-03-18 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
| JP2004501624A (ja) | 2000-06-28 | 2004-01-22 | ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー | Ｐｄ−ｌ２分子：新規ｐｄ−１リガンドおよびその使用 |
| FR2814642B1 (fr) | 2000-10-03 | 2005-07-01 | Ass Pour Le Dev De La Rech En | Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee |
| KR20030066657A (ko) | 2000-11-15 | 2003-08-09 | 오노 야꾸힝 고교 가부시키가이샤 | Ｐｄ-1 결손 마우스 및 그 용도 |
| AR036993A1 (es) | 2001-04-02 | 2004-10-20 | Wyeth Corp | Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas |
| EP2388590A1 (en) | 2001-04-02 | 2011-11-23 | Dana Farber Cancer Institute | PD-1, a receptor for B7-4, and uses thereof |
| US20040241745A1 (en) | 2001-07-31 | 2004-12-02 | Tasuku Honjo | Substance specific to pd-1 |
| CA2466279A1 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| EP1591527B1 (en) | 2003-01-23 | 2015-08-26 | Ono Pharmaceutical Co., Ltd. | Substance specific to human pd-1 |
| CN109485727A (zh) | 2005-05-09 | 2019-03-19 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
| EP3130350A1 (en) | 2005-06-08 | 2017-02-15 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1)pathway |
| CA2611519A1 (en) | 2005-06-17 | 2006-12-28 | Tolerx, Inc. | Ilt3 binding molecules and uses therefor |
| JP5093097B2 (ja) | 2006-03-03 | 2012-12-05 | 小野薬品工業株式会社 | 細胞表面機能分子の細胞外領域多量体 |
| CN101611054B (zh) * | 2006-10-02 | 2013-12-25 | Ac免疫有限公司 | 针对淀粉状蛋白β的人源化抗体 |
| NZ720288A (en) | 2006-12-27 | 2020-02-28 | Harvard College | Compositions and methods for the treatment of infections and tumors |
| GEP20115337B (en) | 2007-01-10 | 2011-11-25 | St Di Ricerche Di Biologia Molecolare P Angeletti Spa | Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors |
| JP2010520748A (ja) | 2007-02-20 | 2010-06-17 | アナプティスバイオ インコーポレイティッド | 体細胞超変異系 |
| MY149129A (en) | 2007-03-20 | 2013-07-15 | Lilly Co Eli | Anti-sclerostin antibodies |
| EP3176264B1 (en) | 2007-05-30 | 2018-09-26 | Postech Academy-Industry- Foundation | Immunoglobulin fusion proteins |
| NZ600758A (en) | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| US20090028857A1 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
| US20120269806A1 (en) | 2007-08-21 | 2012-10-25 | The General Hospital Corporation | Methods of inducing tolerance |
| US8563314B2 (en) | 2007-09-27 | 2013-10-22 | Sangamo Biosciences, Inc. | Methods and compositions for modulating PD1 |
| RU2542967C2 (ru) | 2007-10-05 | 2015-02-27 | Дженентек, Инк. | Применение антитела против амилоида бета при глазных заболеваниях |
| NZ586675A (en) | 2008-01-08 | 2012-04-27 | Merck Sharp & Dohme | Pharmaceutically acceptable salts of 2-{ 4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| EP2307050A4 (en) | 2008-07-04 | 2012-07-25 | Ono Pharmaceutical Co | USE OF A EFFECTIVENESS MARKER TO OPTIMIZE THE THERAPEUTIC EFFECTIVENESS OF AN ANTI-HUMAN PD-1 ANTIBODY ON CANCERS |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| EP2927240A1 (en) | 2008-08-25 | 2015-10-07 | Amplimmune, Inc. | Compositions of pd-1 antagonists and methods of use |
| EP2342228B1 (en) | 2008-09-12 | 2017-09-06 | Oxford University Innovation Limited | Pd-1 specific antibodies and uses thereof |
| EP2342229A1 (en) | 2008-09-12 | 2011-07-13 | ISIS Innovation Limited | Pd-1 specific antibodies and uses thereof |
| ES2592216T3 (es) | 2008-09-26 | 2016-11-28 | Dana-Farber Cancer Institute, Inc. | Anticuerpos anti-PD-1, PD-L1 y PD-L2 humanos y sus usos |
| KR101050829B1 (ko) | 2008-10-02 | 2011-07-20 | 서울대학교산학협력단 | 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제 |
| CN102282265B (zh) | 2008-11-28 | 2020-07-24 | 埃默里大学 | 用于治疗传染病和肿瘤的方法 |
| US8741295B2 (en) | 2009-02-09 | 2014-06-03 | Universite De La Mediterranee | PD-1 antibodies and PD-L1 antibodies and uses thereof |
| WO2011056772A1 (en) | 2009-11-04 | 2011-05-12 | Schering Corporation | Engineered anti-tslp antibody |
| EP2519544A1 (en) | 2009-12-29 | 2012-11-07 | Emergent Product Development Seattle, LLC | Polypeptide heterodimers and uses thereof |
| WO2011100841A1 (en) | 2010-02-16 | 2011-08-25 | Valorisation-Recherche, Limited Partnership | Pd-1 modulation and uses thereof for modulating hiv replication |
| TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| EP2545078A1 (en) | 2010-03-11 | 2013-01-16 | UCB Pharma, S.A. | Pd-1 antibody |
| EP2547365A1 (en) | 2010-03-17 | 2013-01-23 | Abbott Research B.V. | Anti-nerve growth factor (ngf) antibody compositions |
| CA2793309A1 (en) | 2010-03-17 | 2011-09-22 | Anaptysbio, Inc. | Method of producing transcripts using cryptic splice sites |
| US9163087B2 (en) | 2010-06-18 | 2015-10-20 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions |
| KR20130049196A (ko) | 2010-08-05 | 2013-05-13 | 에프. 호프만-라 로슈 아게 | 항-mhc 항체 항-바이러스성 사이토카인 융합 단백질 |
| WO2012021851A2 (en) | 2010-08-12 | 2012-02-16 | Beth Israel Deaconess Medical Center | Methods and compositions for diagnosing and treating lupus |
| WO2012031122A2 (en) | 2010-09-03 | 2012-03-08 | Immport Therapeutics, Inc. | Methods and compositions for the diagnosis and treatment of cancer and autoimmune disorders |
| US9029315B2 (en) | 2010-11-11 | 2015-05-12 | The University Of Hong Kong | Soluble PD-1 variants, fusion constructs, and uses thereof |
| CA2830349C (en) | 2011-03-17 | 2019-07-16 | The University Of Birmingham | Re-directed immunotherapy |
| US9220776B2 (en) | 2011-03-31 | 2015-12-29 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to human programmed death receptor PD-1 and related treatments |
| CN102836441B (zh) | 2011-06-24 | 2019-06-11 | 台北荣民总医院 | 于感染性与恶性疾病的治疗中提升免疫反应的方法 |
| AR087405A1 (es) | 2011-08-01 | 2014-03-19 | Genentech Inc | Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek |
| WO2013022091A1 (ja) | 2011-08-11 | 2013-02-14 | 小野薬品工業株式会社 | Ｐｄ－１アゴニストからなる自己免疫疾患治療剤 |
| CA2845536A1 (en) | 2011-08-15 | 2013-02-21 | Amplimmune, Inc. | Anti-b7-h4 antibodies and their uses |
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| WO2013169693A1 (en) | 2012-05-09 | 2013-11-14 | Bristol-Myers Squibb Company | Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody |
| US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| WO2013177102A2 (en) | 2012-05-21 | 2013-11-28 | Felder Mitchell S | Treatment of cancer by manipulating the immune system |
| WO2013174997A1 (en) | 2012-05-25 | 2013-11-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of refractory haematological malignancies |
| EP2855528B1 (en) | 2012-05-31 | 2019-06-19 | Genentech, Inc. | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists |
| HRP20210122T1 (hr) | 2013-05-02 | 2021-04-16 | Anaptysbio, Inc. | Protutijela usmjerena protiv programirane smrti-1 (pd-1) |
| PE20160953A1 (es) | 2013-12-12 | 2016-09-26 | Shanghai hengrui pharmaceutical co ltd | Anticuerpo pd-1, fragmento de union al antigeno de este y uso medico de este |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| EP3114144A1 (en) | 2014-03-05 | 2017-01-11 | Bristol-Myers Squibb Company | Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent |
| ME03558B (me) | 2014-03-14 | 2020-07-20 | Novartis Ag | Molekuli anti-lag-3 antiтela i njihove upotrebe |
| WO2015145360A1 (en) | 2014-03-24 | 2015-10-01 | Glennie Martin J | Modified antibodies containing modified igg2 domains which elicit agonist or antagonistic properties and use thereof |
| DK3157956T3 (da) | 2014-06-19 | 2020-04-27 | Regeneron Pharma | Ikke-humane dyr med et humaniseret gen med programmeret celledød 1 |
| CA2957258C (en) | 2014-08-05 | 2023-11-07 | MabQuest SA | Immunological reagents |
| WO2016029073A2 (en) * | 2014-08-22 | 2016-02-25 | Bristol-Myers Squibb Company | Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody |
| EA201790737A1 (ru) | 2014-10-03 | 2017-08-31 | Новартис Аг | Комбинированная терапия |
| MX382902B (es) | 2014-10-31 | 2025-03-13 | Oncomed Pharm Inc | Inhibidor de la vía noth en combinación con un agente inmunoterapéutico para usarse en el tratamiento de cáncer. |
| MA41217A (fr) | 2014-12-19 | 2017-10-24 | Advaxis Inc | Polythérapies ayant des souches de listeria recombinées |
| WO2016100882A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Combination therapies |
| CA2971734C (en) | 2014-12-22 | 2025-11-18 | Enumeral Biomedical Holdings Inc | Anti-pd-1 antibodies |
| CA2972757A1 (en) | 2014-12-31 | 2016-07-07 | Arthur M. Krieg | Combination tumor immunotherapy |
| WO2016112870A1 (en) | 2015-01-16 | 2016-07-21 | Tse-Wen Chang | Molecular constructs with targeting and effector elements |
| MA41463A (fr) | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
| SG10201909173PA (en) | 2015-04-01 | 2019-11-28 | Anaptysbio Inc | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) |
| NZ735820A (en) * | 2015-04-17 | 2025-02-28 | Bristol Myers Squibb Co | Compositions comprising a combination of an anti-pd-1 antibody and another antibody |
| JP2018515474A (ja) | 2015-04-28 | 2018-06-14 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｐｄ−１抗体を使用するｐｄ−ｌ１陽性黒色腫の処置 |
| DK3317301T3 (da) | 2015-07-29 | 2021-06-28 | Immutep Sas | Kombinationsterapier omfattende antistofmolekyler mod lag-3 |
| EP3478286B1 (en) | 2016-06-29 | 2024-01-03 | Tesaro, Inc. | Methods of treating ovarian cancer |
| EP3666794A1 (en) * | 2016-11-01 | 2020-06-17 | AnaptysBio, Inc. | Antibodies directed against programmed death- 1 (pd-1) |
| EP3689419A1 (en) | 2016-11-01 | 2020-08-05 | AnaptysBio, Inc. | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) |
| TW201825512A (zh) * | 2016-11-29 | 2018-07-16 | 美商提薩羅有限公司 | 針對計劃性死亡-１（ｐｄ-１）之抗體 |
| CN110382545A (zh) | 2017-01-09 | 2019-10-25 | 泰萨罗公司 | 用抗pd-1抗体治疗癌症的方法 |
| CN110382000A (zh) | 2017-01-09 | 2019-10-25 | 泰萨罗公司 | 用抗tim-3抗体治疗癌症的方法 |
| CA3076515A1 (en) | 2017-09-30 | 2019-04-04 | Tesaro, Inc. | Combination therapies for treating cancer |
| TWI852940B (zh) | 2018-09-04 | 2024-08-21 | 美商泰沙羅公司 | 治療癌症之方法 |
-
2018
- 2018-01-09 CN CN201880016132.XA patent/CN110382545A/zh active Pending
- 2018-01-09 SG SG10201913075RA patent/SG10201913075RA/en unknown
- 2018-01-09 EP EP18704101.7A patent/EP3565844B8/en active Active
- 2018-01-09 CA CA3049440A patent/CA3049440A1/en active Pending
- 2018-01-09 SG SG11201906192SA patent/SG11201906192SA/en unknown
- 2018-01-09 KR KR1020197023407A patent/KR102606252B1/ko active Active
- 2018-01-09 AU AU2018206481A patent/AU2018206481B2/en active Active
- 2018-01-09 HU HUE18704101A patent/HUE061842T2/hu unknown
- 2018-01-09 MX MX2019008207A patent/MX2019008207A/es unknown
- 2018-01-09 TW TW107100822A patent/TWI767976B/zh active
- 2018-01-09 WO PCT/US2018/013029 patent/WO2018129559A1/en not_active Ceased
- 2018-01-09 IL IL267804A patent/IL267804B2/en unknown
- 2018-01-09 US US16/476,536 patent/US11407830B2/en active Active
- 2018-01-09 DK DK18704101.7T patent/DK3565844T5/da active
- 2018-01-09 PT PT187041017T patent/PT3565844T/pt unknown
- 2018-01-09 PL PL18704101.7T patent/PL3565844T3/pl unknown
- 2018-01-09 MA MA047208A patent/MA47208A/fr unknown
- 2018-01-09 BR BR112019014187-1A patent/BR112019014187A2/pt unknown
- 2018-01-09 EP EP23158731.2A patent/EP4219563A3/en active Pending
- 2018-01-09 FI FIEP18704101.7T patent/FI3565844T3/fi active
- 2018-01-09 ES ES18704101T patent/ES2945745T3/es active Active
- 2018-01-09 JP JP2019537103A patent/JP7110206B6/ja active Active
-
2019
- 2019-06-28 ZA ZA2019/04316A patent/ZA201904316B/en unknown
-
2022
- 2022-04-11 JP JP2022065095A patent/JP2022082809A/ja active Pending
- 2022-07-15 US US17/812,933 patent/US12415855B2/en active Active
-
2025
- 2025-01-30 AU AU2025200639A patent/AU2025200639A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3565844T3 (fi) | Menetelmiä syövän hoitamiseksi anti-pd-1 -vasta-aineilla | |
| JP2019536806A5 (enExample) | ||
| JP2018508483A5 (enExample) | ||
| JP2020508317A5 (enExample) | ||
| JP2017506217A5 (enExample) | ||
| JP2018501254A5 (enExample) | ||
| HRP20211058T1 (hr) | Kombinirane terapije koje sadrže molekule antitijela protiv lag-3 | |
| JP2018520657A5 (enExample) | ||
| IL291926B1 (en) | FGFR2 inhibitors alone or in combination with immunostimulating agents in cancer treatment | |
| HRP20210440T1 (hr) | Kombinirana terapija za rak | |
| IL292193B1 (en) | Anti-b7-h1 antibodies for treating tumors | |
| JP2018508512A5 (enExample) | ||
| FI3551660T3 (fi) | Anti-ctla-4-vasta-aineita ja niiden käyttömenetelmiä | |
| HRP20240338T1 (hr) | Imunomodulacija i liječenje solidnih tumora s protutijelima koja se specifično vežu na cd38 | |
| HRP20180147T1 (hr) | Cea protutijela | |
| FI3083694T3 (fi) | Kaninisoituja hiiren anti-koira-pd-1 -vasta-aineita | |
| SI2691112T1 (en) | STABILITY FORMULATION PROTITELES FOR HUMAN PROGRAMMED DEPRESSOR RECEPTOR PD-1 AND RELATED HEALTH | |
| HRP20212034T1 (hr) | Izoformno selektivni inhibitori tgfbeta1 i njihove uporabe | |
| FI3353210T3 (fi) | Tigit-vasta-aineita ja käyttömenetelmiä | |
| WO2015200806A3 (en) | Humanized anti-tau antibodies | |
| PE20231958A1 (es) | Moleculas de union a pd-1 y metodos de uso de las mismas | |
| RU2018125603A (ru) | Комбинация ингибитора с-мет с молекулой антитела к pd-1 и ее применения | |
| IL308805B1 (en) | Anti-pd-1 antibodies for treatment of lung cancer | |
| JP2017501157A5 (enExample) | ||
| RU2020142534A (ru) | Композиция для лечения рака, объединяющая анти-cd26 антитело и другое противораковое средство |